Crown Bioscience
History
| Year | Detail |
|---|---|
| 2006 | Crown Bioscience was founded as a drug discovery and development company, and is now a global contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. |
| 2013 | The company acquired Preclinical Oncology Services Ltd. to expand its oncology services and gain a European footprint. This acquisition strengthened its position as a global supplier of oncology services. |
| 2013 | The company established its bioluminescence imaging platform as part of the acquisition of PRECOS Ltd. |
| 2017 | Crown Bioscience acquired Molecular Response's patient-derived xenograft (PDX) business to expand its in vivo oncology and metabolic disease models portfolio. |
| 2018 | JSR Corp. acquired Crown Bioscience for around $400 million. This acquisition integrated Crown Bioscience as a wholly-owned subsidiary of JSR Life Sciences, creating a more comprehensive, integrated service provider to assist biopharmaceutical companies in drug development. |
| 2021 | Crown Bioscience acquired OcellO B.V., a privately owned contract research organization in the Netherlands. This acquisition will expand its portfolio of in vitro services, integrating OcellO's expertise in high content imaging alongside CrownBio's in vitro and in vivo screens and immunotherapy assessment services. |
BCC Research Beacon 